Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway

被引:132
作者
Fang, Zhiqing [1 ,2 ,3 ]
Tang, Yueqing [1 ]
Fang, Juanjuan [4 ]
Zhou, Zunlin [1 ]
Xing, Zhaoquan [1 ]
Guo, Zhaoxin [1 ]
Guo, Xiaoyu [5 ]
Wang, Weichang [1 ]
Jiao, Wei [1 ]
Xu, Zhonghua [1 ]
Liu, Zhaoxu [1 ,5 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Urol, Jinan, Shandong, Peoples R China
[2] Shandong Univ, Qilu Hosp, Chinese Minist Educ, Key Lab Cardiovasc Remodeling & Funct Res, Jinan, Shandong, Peoples R China
[3] Shandong Univ, Qilu Hosp, Chinese Minist Publ Hlth, Jinan, Shandong, Peoples R China
[4] Wucheng Peoples Hosp, Dept Anesthesiol, Wucheng, Shandong, Peoples R China
[5] Shandong Univ, Sch Nursing, Jinan, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
COA REDUCTASE INHIBITORS; STATINS; THERAPY; PROLIFERATION; INFLAMMATION; APOPTOSIS; INTERLEUKIN-6; NEOADJUVANT; CARCINOMA; IMMUNITY;
D O I
10.1371/journal.pone.0062823
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Renal cell carcinoma (RCC) is the most lethal type of genitourinary cancer due to its occult onset and resistance to chemotherapy and radiation. Recently, accumulating evidence has suggested stains, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, were associated with the risk reduction of cancer. In the present study, we aimed to investigate the potential effects of simvastatin on RCC cells and the underlying mechanisms by which simvastatin exerted its actions. With cell viability, colony formation, and flow cytometric apoptosis assays, we found that simvastatin potently suppressed cell growth of A498 and 786-O cells in a time- and dose- dependent manner. Consistently, the xenograft model performed in nude mice exhibited reduced tumor growth with simvastatin treatment. In addition, the inhibitory effects of simvastatin on migration and invasion were also observed in vitro. Mechanically, we presented that simvastatin could suppress the proliferation and motility of RCC cells via inhibiting the phosphorylation of AKT, mTOR, and ERK in a time- and dose- dependent manner. Further investigation of the underlying mechanism revealed simvastatin could exert the anti-tumor effects by suppressing IL-6-induced phosphorylation of JAK2 and STAT3. In conclusion, these findings suggested that simvastatin-induced apoptosis and its anti-metastasis activity in RCC cells were accompanied by inhibition of AKT/mTOR, ERK, and JAK2/STAT3 pathways, which imply that simvastatin may be a potential therapeutic agent for the treatment of RCC patients.
引用
收藏
页数:13
相关论文
共 58 条
[1]
[Anonymous], HLTH TECHNOL ASSESS
[2]
A survey of therapy for advanced renal cell carcinoma [J].
Basso, Michele ;
Cassano, Alessandra ;
Barone, Carlo .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (02) :121-133
[3]
Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials [J].
Bex, Axel ;
Jonasch, Eric ;
Kirkali, Ziya ;
Mejean, Arnaud ;
Mulders, Peter ;
Oudard, Stephane ;
Patard, Jean-Jacques ;
Powles, Thomas ;
van Poppel, Hendrik ;
Wood, Christopher G. .
EUROPEAN UROLOGY, 2010, 58 (06) :819-828
[4]
The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[5]
BLAY JY, 1992, CANCER RES, V52, P3317
[6]
The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis [J].
Blum, A. ;
Shamburek, R. .
ATHEROSCLEROSIS, 2009, 203 (02) :325-330
[7]
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells [J].
Bocci, G ;
Fioravanti, A ;
Orlandi, P ;
Bernardini, N ;
Collecchi, P ;
Del Tacca, M ;
Danesi, R .
BRITISH JOURNAL OF CANCER, 2005, 93 (03) :319-330
[8]
STATs in oncogenesis [J].
Bowman, T ;
Garcia, R ;
Turkson, J ;
Jove, R .
ONCOGENE, 2000, 19 (21) :2474-2488
[9]
The differential effects of statins on the metastatic behaviour of prostate cancer [J].
Brown, M. ;
Hart, C. ;
Tawadros, T. ;
Ramani, V. ;
Sangar, V. ;
Lau, M. ;
Clarke, N. .
BRITISH JOURNAL OF CANCER, 2012, 106 (10) :1689-1696
[10]
HMG-CoA reductase inhibitors and the kidney [J].
Campese, V. M. ;
Park, J. .
KIDNEY INTERNATIONAL, 2007, 71 (12) :1215-1222